Sichuan, China

Zongjun Shi

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 6.4

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Chengdu, CN (2020)
  • Sichuan, CN (2023)

Company Filing History:


Years Active: 2020-2025

Loading Chart...
Loading Chart...
3 patents (USPTO):

Title: Zongjun Shi: Innovator in Pharmaceutical Chemistry

Introduction

Zongjun Shi is a notable inventor based in Sichuan, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target specific biological pathways. With a total of 3 patents to his name, his work has the potential to impact the treatment of various respiratory diseases.

Latest Patents

One of Zongjun Shi's latest patents is focused on a nitrile derivative that acts as an inhibitor of dipeptidyl peptidase 1. This compound, represented by a specific formula, includes various forms such as stereoisomers, deuterated products, co-crystals, solvates, or pharmaceutically acceptable salts. The compound exhibits dipeptidyl peptidase 1 inhibitory activity, making it a candidate for drug development aimed at treating obstructive airway diseases, bronchiectasis, cystic fibrosis, asthma, emphysema, and chronic obstructive pulmonary diseases.

Career Highlights

Zongjun Shi has worked with prominent companies in the pharmaceutical industry, including Haisco Pharmaceuticals and Sichuan Haiso Pharmaceutical Co., Ltd. His experience in these organizations has allowed him to refine his expertise in drug development and innovation.

Collaborations

Zongjun has collaborated with notable colleagues such as Yao Li and Bo Xu, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Zongjun Shi's work in pharmaceutical chemistry exemplifies the impact of innovative research on healthcare. His patents and collaborations highlight his commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…